A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Impulsive Aggression Comorbid With ADHD

Interventions

DRUG: SPN-810
DRUG: Placebo

Sponsor

Supernus Pharmaceuticals, Inc.